Abstract 615P
Background
Vascular endothelial growth factor receptor (VEGFR) inhibitors have demonstrated promising activity for recurrent and unresectable osteosarcoma. However, the use of VEGFR inhibitor for pulmonary metastatic osteosarcoma to improve resectability and postoperative outcome remains unexplored.
Methods
We did a single-arm phase 2 trial investigating the efficacy of adding anti-angiogenics to chemo for resectable pulmonary metastases (PMs) of osteosarcoma. Pts received VEGFR inhibitor Apatinib plus gemcitabine-docetaxel for 3 cycles pre- and 4 cycles post-metastasectomy, followed by Apatinib monotherapy maintenance until disease progression or unacceptable toxicities. Our primary endpoint was 12-month progression-free rate (12m-PFR) with a historical control of <30%. The primary endpoint would be met if ≥17 out of 39 evaluable pts were considered non-progression, corresponding to a pre-specified 12m-PFR of 50%.
Results
We enrolled 43 pts from Mar 2019 to Nov 2022 in this study, with 23 (54%) having ≥4 PMs, 12 (28%) having ≥10 PMs, and 24 (56%) having bilateral PMs. Extra tiny PMs were commonly detected and resected during surgical exploration. 39/43 pts (91%) finished their surgical procedures as planned, while 1 pt encountered tumor progression before metastasectomy and 3 failed to undergo the 2nd-stage metastasectomy after the 1st stage. Two pts were excluded from efficacy analysis due to major protocol violations. Of the remaining 41 pts, tumor volume reduction was seen in 30 (73.2%) pts before surgery, and 18 of the first 39 evaluable pts were progression-free at 12m (primary endpoint met). In the safety analysis (43 pts), ≥grade 3 toxicities were noticed in 29(67%) pts. One of the 15 deaths was due to post-operative complications and the remaining (14/15) due to tumor progression. The most common grade 3–4 toxicies were thrombocytopenia (26%), proteinuria (16%), anemia (14%), granulocytopenia(12%), pain(9.3%), pneumothorax(9.3%). Of note, only 2 ≥grade 3 postoperative wound problems following VEGFR inhibitor were observed.
Conclusions
Our study demonstrated a potential activity of combining Apatinib plus chemotherapy with metastasectomy for treating pulmonary metastatic osteosarcoma.
Clinical trial identification
NCT03742193.
Editorial acknowledgement
We are wholeheartedly gratefull to all participants and their parents in this study.
Legal entity responsible for the study
Ruijin Hospital, Shanghai Jiaotong University.
Funding
Shanghai Municipal Health Commission (grant No. 202140124) National Science Foundation of China (grant No. 82141116) Natural Science Foundation of Shanghai (grant No. 20ZR1434000).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract